Enhanced Oncolytic Virus System for Improved Safety and Efficacy

The present inventive concept relates to an enhanced oncolytic virus system, comprising a recombinant oncolytic virus vector, synergistic anti-tumor agents, and cytokine expression, resulting in improved safety and enhanced anticancer efficacy.

The original patent disclosed an oncolytic virus with improved safety and anticancer effect. However, the existing invention has limitations in terms of substrate specificity, toxicity, and storage stability. The present inventive concept addresses these limitations by introducing a system that combines the oncolytic virus vector with synergistic anti-tumor agents, cytokine expression, and stabilizing agents, thereby enhancing the overall safety and efficacy of the treatment.

The enhanced oncolytic virus system comprises a recombinant oncolytic virus vector engineered to express a cytokine, which enhances the immune response and tumor targeting. The vector is administered in combination with a synergistic anti-tumor agent, resulting in enhanced anticancer efficacy. Additionally, the vector is optimized for improved substrate specificity and reduced toxicity. A pharmaceutical composition comprising the recombinant oncolytic virus vector and a stabilizing agent is formulated for improved storage stability and shelf life. Furthermore, the oncolytic effect of the vector can be enhanced by co-administering it with a proteasome inhibitor, thereby increasing the vector's half-life and anticancer activity.

The new claims introduce a synergistic combination of the oncolytic virus vector with anti-tumor agents, cytokine expression, and stabilizing agents, which is not obvious from the original patent. The optimization of the vector for improved substrate specificity and reduced toxicity, as well as the formulation of the pharmaceutical composition, are also novel and non-obvious aspects of the inventive concept.

Alternative embodiments of the inventive concept may include using different types of synergistic anti-tumor agents, varying the cytokine expression, or employing different stabilizing agents. Additionally, the oncolytic virus vector could be engineered to express different proteins or peptides to enhance its anticancer effect.

The enhanced oncolytic virus system has significant commercial potential in the treatment of various types of cancer, including solid tumors and hematological malignancies. The target market includes pharmaceutical companies, biotechnology firms, and research institutions focused on cancer therapy.